Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 13, Issue 4, 2013, Pages 430-434

  Wetzler, Meir ^a   Thomas, Debora A ^b   Wang, Eunice S ^a   Shepard, Robert ^c   Ford, Laurie A ^a   Heffner, Thompson L ^d   Parekh, Samir ^e   Andreeff, Michael ^b   O'Brien, Susan ^b   Kantarjian, Hagop M ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Callisto Pharmaceuticals Inc   (United States)

^d EMORY UNIVERSITY   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Clinical trial; Refractory disease; Relapsed disease

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; ANNAMYCIN; ASPARTATE AMINOTRANSFERASE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIPHENHYDRAMINE; DOXORUBICIN; LIDOCAINE; LIPOSOME; LIVER ENZYME; PALIFERMIN; RITUXIMAB; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTEREMIA; BLINDNESS; BLOOD CLOTTING DISORDER; CELLULITIS; CEREBELLUM HEMORRHAGE; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; EPIDIDYMITIS; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOTENSION; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LEUKOPENIA; LIPOSOMAL DELIVERY; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; NAUSEA; NEUTROPENIA; OPEN STUDY; PAPULE; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; RECOMMENDED DRUG DOSE; SHORT TERM MEMORY; SIDE EFFECT; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; TYPHLITIS; WEAKNESS;

CLINICAL TRIAL; REFRACTORY DISEASE; RELAPSED DISEASE;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; FEMALE; HUMANS; LIPOSOMES; MALE; MIDDLE AGED; NANOPARTICLES; NEOPLASM GRADING; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; YOUNG ADULT;

EID: 84880712014     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.03.015     Document Type: Article

References (16)

1. D.J. DeAngelo Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma Hematol Oncol Clin North Am 23 2009 1121 1135 vii-iii
2. FDA approves liposomal vincristine (Marqibo) for rare leukemia Oncology (Williston Park) 26 2012 841
3. A. Tafuri, C. Gregorj, and M.T. Petrucci MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia Blood 100 2002 974 981 (Pubitemid 34832626)
4. W. Priebe, and R. Perez-Soler Design and tumor targeting of anthracyclines able to overcome multidrug resistance: a double-advantage approach Pharmacol Ther 60 1993 215 234 (Pubitemid 24117376)
5. U. Consoli, W. Priebe, and Y.H. Ling The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines Blood 88 1996 633 644 (Pubitemid 26240395)
6. D.J. Booser, R. Perez-Soler, and P. Cossum Phase I study of liposomal annamycin Cancer Chemother Pharmacol 46 2000 427 432
7. D.J. Booser, F.J. Esteva, and E. Rivera Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer Cancer Chemother Pharmacol 50 2002 6 8 (Pubitemid 34743989)
8. H.M. Kantarjian, S. O'Brien, and T.L. Smith Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia J Clin Oncol 18 2000 547 561 (Pubitemid 30078536)
9. D.A. Thomas, S. O'Brien, and S. Faderl Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia J Clin Oncol 28 2010 3880 3889
10. A. Zeidan, E.S. Wang, and M. Wetzler Pegasparaginase: where do we stand? Expert Opin Biol Ther 9 2009 111 119
11. M. Wetzler, B.L. Sanford, and J. Kurtzberg Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511 Blood 109 2007 4164 4167 (Pubitemid 46743378)
12. D. Douer, H. Yampolsky, and L.J. Cohen Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia Blood 109 2007 2744 2750 (Pubitemid 46482066)
13. J. Cortes, S. O'Brien, and E. Estey Phase I study of liposomal daunorubicin in patients with acute leukemia Invest New Drugs 17 1999 81 87 (Pubitemid 29452751)
14. D. Russo, P.P. Piccaluga, and M. Michieli Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia Ann Hematol 81 2002 462 466 (Pubitemid 36067660)
15. M. Offidani, L. Corvatta, and R. Centurioni High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia Hematol J 4 2003 47 53 (Pubitemid 36927160)
16. R. Perez-Soler, and W. Priebe Anthracycline antibiotics with high liposome entrapment: structural features and biological activity Cancer Res 50 1990 4260 4266 (Pubitemid 20225661)